Researchers found patients taking canagliflozin had more improvement in A1C levels than those taking DPP-4 inhibitors, and those taking canagliflozin were more likely to achieve key thresholds ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Data derived from: D ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors had a lower risk for rheumatic disease ...

Peter Salgo, MD: Let’s talk about some of these new drugs. There are new treatment classes for type 2. We’ve got, what, the GLP-1s [glucagon-like peptide-1 receptor agonists] and the DPP-4s ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

CSPC Pharmaceutical Group Ltd. on Jan. 13 gained the National Medical Products Administration’s approval of Shanzeping (prusogliptin tablets; DBPR-108) as a novel oral dipeptidyl peptidase-IV (DPP-4) ...

Woman-stomach-pain-pills_G_477841604 Patients with type 2 diabetes have a greater risk for developing inflammatory bowel disease when using dipeptidyl peptidase-4 inhibitors. In patients with type 2 ...

Among people with type 2 diabetes, new treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor was linked with higher risk of a rare blistering skin condition, researchers reported. Compared with ...